有观点,有态度这是医业观察的第2548-4期文章来源:医药投资部落沉舟侧畔千帆过,病树前头万木春。2025年,当数量不菲的港股医药股开始不断创下历史新高的时候,诺辉健康的股东们却越来越揪心。2025年6月25日,作为诺辉基金的股东之一,长城基金再次公告下调诺辉健康的估值为1.2港元/股。相比于诺辉健康停牌前的14.14港元/股,长城基金给出的最新估值,已经下调了超过90%。但是这个估值下调幅度,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.